
A source-linked scan of the September 11-18 capital-markets window: the Fed's first rate hike since 2023 and Orion180's below-range IPO, a $7.7 billion broker take-private, new SEC proposals on shareholder votes and tokenized stocks, and a $2.17 billion LBO term loan.
| Area | Event | Stage and scale | Parties / advisers | Immediate read-through |
|---|---|---|---|---|
| IPO | Electra Therapeutics (ETRA) | Priced September 17; upsized to 23,333,334 shares at $15.00 for roughly $350 million gross; trading from September 18, closing September 21 | Jefferies, TD Cowen, Evercore ISI and Cantor as joint book-running managers | The largest biotech pricing of the post-Labor Day window; price the registrational sHLH program against a 3,500,000-share option. 6 |
| IPO | Orion180 Insurance Group (OIG) | Priced September 17 at $12.00, below the $15.00–$17.00 range filed September 9; 20 million shares for $240 million | RBC Capital Markets, UBS Investment Bank and Raymond James as lead book-running managers | A 20% cut below the bottom of the range is the clearest single read on how the rate week landed on primary-market demand. 3 |
| IPO | Syngenta Group | Confidentially filed for a Hong Kong listing September 15; at least $5 billion, potentially $10 billion; launch targeted for late 2026 or early 2027 | Sinochem (controlling shareholder); CEO Hengde Qin | At $10 billion it would be Hong Kong's largest listing since 2010, testing appetite for a group that Sinochem took private for $43 billion in 2017 and has never marked publicly. 7 |
| M&A | The Baldwin Group (BWIN) | Definitive agreement September 14; $7.7 billion deal value; $32.50 a share in cash, about an 88% premium to the June 17 close | Sequence Holdings and DFO Management, Michael Dell's family office | A non-sponsor buyer paying an 88% premium resets the reference price for mid-market insurance distribution. 8 |
| M&A | Grab / Atome Financial | Announced September 15; 60% for $1.49 billion, with the remaining 40% about two years after closing under a framework tied to Atome's EBITDA and revenue; values the target at $2 billion to $4.5 billion; completion expected by Q3 2027 | Grab (GRAB); Atome Financial | Because the second tranche is performance-linked, most of the valuation risk sits past the first close. 9 |
| M&A | Brookfield / Reliance Worldwide | Agreed September 16; almost $2.9 billion; $3.38 a share in cash, matching the earlier A$4.75 offer; shareholder vote required | Brookfield (BN.TO); AustralianSuper and Aware Super hold about 20.2% of Reliance | Two pension funds that rejected a Brookfield bid once before control the outcome. 10 |
| Regulation | SEC shareholder-proposal and annual-report proposals | Proposed September 16; would end SEC review of shareholder proposals and drop the glossy annual-report requirement; comment period open | SEC Chair Paul S. Atkins | Removes the federal route for including or excluding a proposal and shifts the contest to state corporate law. 11 |
| Regulation | SEC tokenized-securities exemption | Issued September 17; five-year exemption from exchange rules for platforms trading tokenized stocks, plus a dealer-registration carve-out for liquidity providers | SEC | Issuer notification and an issuer veto are conditions; synthetic tokens are excluded. 12 |
| Regulation | CFTC v. Michael Frederick Staryk | Default judgment entered September 15 in the District of Connecticut; $547,616 restitution plus a $5,907,720 civil penalty, permanent trading and registration bans | CFTC; relief defendants Yvonne Stephanie Solerti-Coto and Global Financial Institution LLC ordered to disgorge $110,509.86 | The penalty-to-restitution multiple of roughly 11x is the number to carry into retail solicitation risk assessments. 13 |
| Firm guidance | Q3 fee outlook at the Barclays Global Financial Services Conference | September 14–16; industry investment-banking revenue reached $21.194 billion in Q3 through September 15, against $23.765 billion a year earlier | BofA (Brian Moynihan), JPMorgan (Doug Petno), Morgan Stanley (Daniel Simkowitz), Goldman Sachs (David Solomon) | Guidance spread from JPMorgan's mid-to-high-teens fee growth to BofA's decline of more than 10%, with Goldman flagging $500 million of extra non-compensation costs. 1415 |
| Personnel | State Street and Raymond James | State Street appointments effective September 14; Raymond James Bank Segment succession announced September 15, effective January 1, 2027 | Mostapha Tahiri and Ann Fogarty (State Street); Steve Raney, Scott Curtis and Tarek Helal (Raymond James) | Both moves consolidate platform and banking oversight under executives who already ran adjacent businesses. 1617 |
| Financing | Goldman Sachs Alternatives private-equity close | Final close September 15; $11.7 billion raised across private-equity funds and related vehicles, led by $9.6 billion for West Street Capital Partners IX | Goldman Sachs Alternatives | A single sponsor raising $11.7 billion in one close is the clearest signal that LP commitments survived the July AI-trade unwind. 1819 |
| Financing | PANTHERx Rare LBO term loan | Launched September 18; $2.17 billion seven-year covenant-lite first-lien term loan, price talk S+300 area with an OID of 99.5; commitments due 5 p.m. ET on September 24 | JPMorgan leads a 14-bank arranger group and is administrative agent; Warburg Pincus leads the buyer group | A roughly $7.5 billion LBO moving from private credit to the syndicated loan market is the week's clearest test of institutional demand at these yields. 20 |
federalreserve.gov
financialcontent.com
biopharmadive.com
insurancebusinessmag.com
finance.yahoo.com
uk.finance.yahoo.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.